Medical Journal Articles


ledipasvir sofosbuvir amy colson Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner JW, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM., Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchinson JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, & Sulkowski M. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England Journal of Medicine. July 21, 2015. doi:10.1056/NEJMoa1501315
pdf-preview Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies. HIV Clinical Trials. 14(3):81–91 May-Jun 2013. Thomas Land Publishers. doi:10.1310/hct1403-81
journal 1 Zolopa A, Sax P, DeJesus E, Mills A, Cohen CJ, Wohl D, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. May 2013.
 HIVEssentialsCover Sax PE, Cohen CJ, Kuritzkes DR, eds. HIV Essentials. Burlington, VT: Jones & Bartlett, 2013.
journal 2 Sax P, DeJesus E, Mills A, Zolopa A, Cohen CJ, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. June 2012; 379(3): 2439-2448.
Phase Elion R, Cohen CJ, et al. on behalf of the GS-US-216-0105 Study Team. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/ tenofovir df in the initial treatment of HIV infection. AIDS. 25(15):1881-6. Sep 24, 2011. PMID 21811136.
Lancet Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. The Lancet. July 2011; 378(9787): 229-237.
journal 4 Skiest DJ, Cohen C, Mouzer K, Haigner Z, Baker D, Gottlieb M, Bellman PC, Dejesus E, Khanlou H, Ruane PJ, Hsiao C-B, Abriola K, Rashbaum B, Bellos N, Ward D, Colson A, et al. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment experienced patients. HIV Clinical Trials. May-June 2011; 13(3): 131-140.
journal 5 Lalezari J, Gathe J, Brinson C, Thompson M, Cohen CJ, DeJesus E, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1–infected, treatment-experienced, CCR5 antagonist–naive subjects. JAIDS. June 2011; 57(2): 118-125.
fumarate Cohen CJ, Elion R et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25 (6):F7-F12. Mar 27, 2011. Wolters Kluwer Health. PMID: 21412057.
journal 6 Cohen CJ, DeJesus E, LaMarca A, Young B, Yau L, Patel L, et al. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. HIV Clinical Trials. September-October 2010; 11(5): 239-247.
journal 7 Mehta S, Cohen CJ, Taylor J. The fourteenth annual HIV drug guide. Positively Aware. March-April 2010.
journal 8 Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum J, et al. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. JAIDS: Journal of Acquired Immune Deficiency Syndromes. April 2010; 53(5): 614-618.
complementary Elion RA, Cohen CJ. Complementary Medicine and HIV Infection. Primary Care. 24: 905-920. 1997. Ross L, Elion R, Lanier R, Dejesus E, Cohen C, et al; COL40263 Study Team. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). AIDS Research and Human Retroviruses. 25(7):665-672. Jul 2009. PMID: 19563238.
journal 9 Cohen CJ. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clinical Trials. March-April 2009; 10(2): 116-124.
journal 10 Boyle BA, Cohen CJ, DeJesus E, et al. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. The AIDS Reader. April 2009; 9(4): 158-160.
journal 11 Cohen CJ. The ARTEMIS trial: Once-daily darunavir/ritonavir in the management of treatment-naïve, HIV-infected patients. HIV Therapy. March 2009; 3(2): 121-133.
journal 12 Horne R, Kovacs C, Katlama C, Clotet B, Fumaz CR, Youle M, Kulasegaram R, Fisher M, Cohen CJ, Slim J, Shalit P, Cooper V, Tsoukas C. Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? AIDS Research and Therapy. February 2009; 6:2.
abstract 3 Arhad S, Rothberg M, Rastegar D, Spooner L, Skiest D. Survey of physican knowledge regarding antiretroviral medications in hospitalized HIV-infected patients. Journal of the International AIDS Society. February 2009; 12:1.
 Capture Cohen CJ, et al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS. 23(3):423-6. Jan 28, 2009. PMID: 19114852.
journal 13 Boyle B, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Antiretroviral treatment update from the 48th ICAAC/46th IDSA Annual Meeting. The AIDS Reader. January 2009; 19(1): 22-31.
abstract 2 Simone M, Appelbaum J. HIV in older adults. Geriatrics: Better Medicine for Midlife and Beyond. December 2008; 63(12): 6-7.
journal 16 Skiest DJ, Kambrink A, Su Z, Robertson KR, Margolis D. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. JAIDS: Journal of Acquired Immune Deficiency Syndromes. December 2008; 49(4): 377-383.
journal 17 Boyle B, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Antiretroviral treatment update from the 17th International AIDS Conference. The AIDS Reader. November 2008; 18(11): 570-579.
Not Available Online Cohen CJ, Colson A, Pierone G, DeJesus E, Kinder F, Elion R, Skiest D, Habel A, Jensen J, Garb J, Schrager H. The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy. Journal of the International AIDS Society 2008. November 10, 2008; 11(Suppl 1):019.
Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen CJ, Harrington R, Kempf D, Zolopa A. Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Antimicrobial Agents and Chemotherapy. 52(11):4050-4056. Nov 2008. Epub Aug 18, 2008. PMID: 18710915.
journal 18 Iarikov D, Duke W, Skiest D. Extensive development of flat warts as a cutane manifestation of immune reconstitution syndrome. The AIDS Reader. October 2008; 18(10): 524-527.
Capture Fätkenheuer G, et al. MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. New England Journal of Medicine. 359(14):1442-1455. Oct 2, 2008. PMID: 18832245.
 Capture Gulick RM, et al. MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. New England Journal of Medicine. 359(14):1429-1441. Oct 2, 2008. PMID: 18832244.
journal 19 Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, et al. Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clinical Infectious Diseases. August 2008; 47(3): 421-4.
journal 20 Vahey MT, Wang Z, Su Z, Nau ME, Rrambrink A, Skiest D, Margolis D. CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Research and Human Retroviruses. August 2008; 24(8): 1047-66.
journal 21 Cenizal M, Hardy RD, Anderson M, Katz K, Skiest D. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes. August 2008; 48(5):567-571.
journal 23 Elion R, Cohen CJ, Ward D, et al for the BATON Study Group. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabline given once daily. HIV Clinical Trials. July-August 2008; 9(4): 213-224.
journal 24 Shah A, Tidswell M, Prefontaine M, Skiest DJ, Pantanowitz L. Choriocarcinoma in an AIDS patient – relapsing but not fatal. International Journal of STD and AIDS. July 2008; 19(7): 496-98.
journal 25 Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. Efficacy and tolerability of long term Efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. January 2008; 22: 275-9.
journal 26 Boyle B, Elion R, Cohen CJ, DeJesus E, Hawkins T, Moyle G. Advances in HIV theraputics: News from the 4th International AIDS Society Conference. The AIDS Reader. October 2007; 17(10):484-490.
abstract 4 Cohen CJ, Colson A. Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens. HIV Clinical Trials. 2007: 8(4):256.
journal 27 Iarikov D, Roberts D, Granowitz E, Skiest D. Invasive aspergillosis presenting as a neck mass in a person with HIV/AIDS. The AIDS Reader. July 2007; 17(7): 343-344.
journal 28 DeJesus E, Rodwick BM, Bowers D, Cohen CJ, & Pearce D. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. Journal of the International Association of Physicians in AIDS Care. June 2007; 6(2): 95-100.
journal 29 Skiest D, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS Clinical Trials Group 5170. The Journal of Infectious Diseases. May 15, 2007; 195(10): 1426-1436.
journal 30 Heelon M, Skiest D, Tereso G, Meade L, Weeks J, Pekow P, Rothberg M. Effect of a clinical pharmacist’s interventions on duration of antiretroviral-related errors in hospitalized patients. American Journal of Health-System Pharmacy. May 2007; 64 (20): 2064-8.
journal 31 Boyle BA, Elion R, Cohen CJ, et al. Advances in HIV therapeutics: The 14th CROI. The AIDS Reader. May 2007; 17(5): 268-286.
journal 32 Sharma A, Awasthi S, Harrod CK. Matlock EF, Khan S, Xu L, Chan S, Yang H, Thammavaram CK, Rasor RA, Burns DK, Skiest DJ, Van Lint C, Girard AM, McGee M, Monnat RJ Jr, Harrod R. The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication. Journal of Biological Chemistry. April 2007; 282(16): 12048-57.
journal 33 Coskun ZU, Mathews D, Weatherall P, Skiest D, Oz OK. Cryptococcal lymphadenitis and massive splenomegaly in an immunocompromised patient. Clinical Nuclear Medicine. April 2007; 32(4): 314-6.
abstract 6 Vazquez JA, Skiest DJ, et al. Safety and efficacy of Posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clinical Trials. March-April, 2007; 8(2): 86-97.
abstract 7 Hill A, Grossman H, Cohen CJ, et al. Modeling-based prediction of clinical benefits from Etravirine in the TMC125-C223 trial. HIV Clinical Trials. March-April 2007; 8(2): 68-76.
journal 34 Haubrich RA, Berger DB, Chiliade PC, Colson AD, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. March 30, 2007; 21(6): F11-F18.
CME/CE Activity – Not Available Online Kessler HA, Boyle BA, Cohen CJ, et al. Assessing best practices in HIV/AIDS therapy. Changing Concepts in HIV Disease (CCHIV); March 2007.
Newest Boyle, BA, Elion R, Cohen CJ, et al. Recent Developments in HIV Therapeutics. The AIDS Reader. 17(3):162-166. Mar 2007. A Cliggott Publication. PMID: 17396334.
abstract 8 Skiest DJ, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clinical Infectious Diseases. February 2007; 44(4): 607-614.
abstract 9 Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, & Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the Five-Days-On-Two-Days-Off (FOTO) study. HIV Clinical Trials. Jan/Feb 2007; 8(1): 19-23.
journal 35 Boyle BA & Cohen CJ. NNRTIs: The next generation approaches. New York, NY: The Body Pro; December 14, 2006.
Not Available Online Cohen CJ. More hope coming with new HIV drugs, classes, and combos. Physician’s Weekly. February 12, 2007; 24(7).
Not Available Online Cohen CJ. The next frontier in HIV: Battling drug resistance. Physician’s Weekly. January 15, 2007; 24(3).
journal 37 Elion R, Cohen CJ, DeJesus E, et al. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study. HIV Clinical Trials. November/December 2006; 7(6): 324-333.
journal 38 El-Sadr WM, Lundgren, JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, et al. CD4+ count-guided interruption of antiretroviral treatment. The New England Journal of Medicine. 2006; 355(22):2283-96.
Not Available Online Boyle BA, Cohen CJ, et al. XVI International AIDS Conference: Part 1. The AIDS Reader. 16(10):517-521. Oct 2006. A Cliggott Publication. PMID: 17096469.
Not Available Online Skiest DJ, Camelo-Piragua S, & Meade L. Painful oral ulcerations in patients with AIDS. The AIDS Reader. October 2006; 16(10): 531-532.
Not Available Online Cohen CJ. Making progress in reducing the pill burden in HIV. Physician’s Weekly. October 9, 2006; 13(38).
journal 40 DeJesus E, Berger D, Markowitz M, Cohen CJ, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2006; 43(1):1-5.
abstract 11 Appelbaum JS, Elion R, Gallant JE, Henry K, Newman MD, Saag MS, Sax PE. Who should be providing HIV care? AIDS Clinical Care. 2006; 18(3): 21-24.
Not Available Online Cohen CJ. Shoot for success. HIV Plus. April 2006:32-33.
journal 41 Trottier B, Walmsley S, Reynes J, Piliero P, O’Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy J, Stellbrink H, Lange J, Kuritzkes D, Eron J, Cohen CJ, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2005;40(4):413-421.
journal 42 Cohen CJ. Ritonavir-boosted protease inhibitors, part 1: Strategies for balancing efficacy with effects on lipids. The AIDS Reader. 2005; 15 (9) 462-5, 470-1, 47, 477.
journal 43 Swindells S, Cohen CJ, Berger DS, et al. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. BioMed Central Infectious Diseases. 2005;5(23).
 Capture Hellinger J, Cohen CJ, et al. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. HIV Clinical Trials. 6(2):107-117. Mar-Apr 2005. PMID: 15983895.
journal 44 Cohen CJ. EuroSIDA study confirms ability of most HAART regimens to decrease rates of illness and death. The Body Pro. February 24, 2005.
 fghdfh Estanislao L, Simpson D, Cohen CJ. Antiretroviral rounds. First holiday was a disaster: should she take another? AIDS Clinical Care. 16(5):40-1. May 2004. PMID: 15199864.
abstract 12 Cohen CJ, Boyle BA. Antiretroviral therapy: The “when to start” debates. Clinical Infectious Disease. 2004;39:1705-1708.
abstract 1 Youle M, Cohen CJ, Katlama C, et al. Co-development of new antiretrovirals in very treatment-experienced HIV-infected individuals. The Lancet. 2004;364 (9439):1036-1037.
journal 45 Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF;T-20) in combination with an optimized background regimen. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2004;37(1):1140-1146.
journal 46 Cohen C. HIV and AIDS: A research and development update. Physician’s Weekly. December 15, 2003; 20(47).
 dfsdfa The LD Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. The Lancet. 361(9359):726-735. Mar 1, 2003. PMID: 12620736.
journal 47 Cohen CJ, Hellinger JA, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clinical Trials. 2003;4(5):347-357.
First-line Treatment in HIV 2003 Cohen C. First-line treatment in HIV: Many paths to success. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2003; 33 (supplement 1): S29-S38.
journal 48 Lalezari JP, Henry K, O’Hearn M, Montaner J, Piliero P, Trottier B, Walmsley S, Cohen CJ, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HI infection in North and South America. The New England Journal of Medicine. 2003;349(22):2175-2185.
journal 49 The LD Study Group, et al. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. The Lancet. 2003;361:726-735.
AIDS Reader 2003 Daar ED, Cohen CJ, Remien R., Sherer R, Smith K. Improving adherence to antiretroviral therapy. The AIDS Reader. 2003;13:81-90.
journal 50 Lalezari JP, Eron JJ, Carlson M, Cohen CJ, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003;17(5):691-698.
journal 51 Cohen CJ, Hunt S, Sension M, et al and the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16(4):579-588.
journal 52 Colson AE, Sax PE, Keller MJ, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2002;30(1):27-32.
journal 53 Wheat LJ, Farthing C, Cohen CJ, et al., for the TIDBID (NR15520/M61018) study team. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection. Antiviral Therapy. 2002;7(3):199-209.
journal 54 Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen CJ, Powderly W. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: Implications for intermittent therapeutic strategies. The Journal of Infectious Diseases. 2002; 186: 851-4.
journal 55 Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care and STDs. 2002;16(7):327-335.
journal 56 Colson AE, Sax PE, Keller MJ, et al. Paronychia in association with indinavir treatment. Clinical Infectious Diseases. 2001;32(January 1):140-143.
journal 57 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. The cost-effectiveness of combination antiretroviral therapy in HIV. New England Journal of Medicine. 2001;344(11):824-831.
journal 58 Weinstein MC, Goldie SJ, Losina E, Cohen CJ et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Annals of Internal Medicine. 2001;134(6):440-450.
Not Available Online Verbiest W, Brown S, Cohen CJ, et al. Prevalence of HIV-1 drug resistance in antiretroviral-naïve patients: a prospective study. AIDS. 2001;15(5):647-650.
amy colson AIDS publication Welles SL, Pitt J, Colgrove R, Mcintosh K, Chung P-H, Colson A, Lockman S, Fowler M-G, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, & Japour AJ. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study AIDS (Hagerstown) 14(3): 263-271. February 18, 2000.
journal 59 Lalezari JP, Beal JA, Ruane PJ, Cohen CJ et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clinical Trials. 2000;1(3):1-15.
journal 60 Hellinger JA, Cohen CJ, Stein A, Gallant J, Gathe J, Keiser, P. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy. HIV Clinical Trials. 2000;1(2):25-28.
Not Available Online Beatty MA, Cohen CJ, Coady W, et al. Expanded access: the experiences of one research site. Research Practitioner. 2000;1(5).
journal 61 Colven R, Harrington RD, Spach DH, Calvin CJ, et al. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Annals of Internal Medicine. 2000;133(6):430-434.
Not Available Online Colson AE, Sax PE. Sexual dysfunction and HIV infection. Aids Clinical Care. 2000;12(3).
journal 62 DeMaria, Jr. A, Kunches L, Mayer K, Cohen CJ et al. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gpl160 working group. Journal of Human Virology. 2000;3(4):182-92.
abstract 15 Cohen CJ, Piliero PJ, Pile OH, et al. Increasing treatment adherence in the correctional setting: Current efforts to simplify protease inhibitor dosing regimens. Journal of Correctional Health Care. 2000;7(1).
journal 63 Cohen CJ, Hellinger JA, Norris D, et al. Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection. The AIDS Reader. 2000;10(5):296-313.
abstract 16 Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ et al. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. The Journal of Infectious Diseases. 2000;181(2):540-547.
journal 64 Morris AB, Cu-Uvin S, Harwell JI, Garb J, Zorrilla C, Vajarant M, Dobles AR, Jones TB, Carlan S, Allen DY. Multicenter Review of Protease Inhibitors in 89 Pregnancies. Journal of Acquired Immune Deficiency Syndromes. 2000;25(4):306-311.
 Capture Cameron DW, Heath-Chiozzi M, Danner S, Cohen CJ, et al. Randomized Placebo Controlled Trial of Ritonavir in Advanced HIV-1 Disease. The Lancet. 351(9102):543-49. 1998 PMID 9492772.